EDIT Management Feasibility Trial (Pre-EDIT)
Primary Purpose
Pleural Effusion, Malignant
Status
Unknown status
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
EDIT Management
Chest drain and talc pleurodesis
Sponsored by
About this trial
This is an interventional treatment trial for Pleural Effusion, Malignant
Eligibility Criteria
Inclusion Criteria:
Clinically confident diagnosis of malignant pleural effusion, defined as any of the following:
- Pleural effusion with histocytologically proven pleural malignancy OR
- Pleural effusion in the context of histocytologically proven malignancy elsewhere, without a clear alternative cause for fluid OR
- Pleural effusion with typical features of malignancy with pleural involvement on cross-sectional imaging (CT/MRI)
- Degree of breathlessness for which therapeutic pleural intervention would be offered
- Age >18 years
- Expected survival > 3 months
- Written Informed Consent
Exclusion Criteria:
- Females who are pregnant or lactating
- Clinical suspicion of non-expansile lung for which talc pleurodesis would not be offered
- Patient preference for 1st-line indwelling pleural catheter (IPC) insertion
- Previous ipsilateral failed talc pleurodesis
- Estimated pleural fluid volume ≤ 1 litre, as defined by thoracic ultrasound
- Any contraindication to chest drain or IPC insertion, including:
Irreversible coagulopathy Inaccessible pleural collection, including lack of suitable IPC tunnel site
- Any contraindication to MRI scanning, including:
Claustrophobia Cardiac pacemaker Ferrous metal implants or retained ferrous metal foreign body Previously documented reaction to Gadolinium-containing intravenous contrast agent Significant renal impairment (eGFR<30 ml/min)
Sites / Locations
- Queen Elizabeth University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
EDIT Management
Standard Care
Arm Description
Outcomes
Primary Outcome Measures
Feasibility of recruiting 30 patients within 12 months and randomising them to either EDIT Management or Standard Care
The number of patients recruited and randomised within 12 months
Secondary Outcome Measures
Failure rate of the manometry procedure
Defined as the proportion of patients in whom PEL cannot be computed
Incidence of adverse events associated with the manometry procedure
Number of participants with Adverse Events (AEs) and Serious AEs (SAEs), defined by United Kingdom Good Clinical Practice in Research, associated with use of the digital pleural manometer
Aspiration threshold to detect abnormal pleural elastance
The pleural fluid aspiration volume at which the rolling average pleural elastance over the preceding 250ml (PEL250) first exceeds the upper limit of normal (14.5cm H2O/L).
Proportion of patients requiring pneumothorax induction following manometry
The proportion of patients in which pneumothorax induction is required to facilitate safe intercostal chest drain/IPC insertion in the EDIT arm (Group A)
Assess accuracy of pleural cavity volume change assumptions
To test the assumption that pleural cavity volume change is equivalent to the volume of pleural fluid removed during aspiration by measuring:
Pleural fluid aspiration volume
Pleural cavity volume change, as measured directly using volumetric Magnetic Resonance Imaging (MRI), calculated as pre- minus post-aspiration pleural cavity volume
Assess accuracy of ultrasound effusion volume estimate
To test the accuracy of a predictive model of pleural effusion volume based on thoracic ultrasound measurements by measuring:
Thoracic ultrasound estimated total pleural effusion volume
Pre-pleural fluid aspiration pleural cavity volume measured by volumetric MRI
Full Information
NCT ID
NCT03319186
First Posted
August 4, 2017
Last Updated
October 22, 2017
Sponsor
NHS Greater Glasgow and Clyde
Collaborators
Rocket Medical plc
1. Study Identification
Unique Protocol Identification Number
NCT03319186
Brief Title
EDIT Management Feasibility Trial
Acronym
Pre-EDIT
Official Title
Pre-EDIT: A Randomised, Feasibility Trial of Elastance-Directed Intra-pleural Catheter or Talc Pleurodesis (EDIT) in the Management of Symptomatic Malignant Pleural Effusion Without Obvious Non-expansile Lung
Study Type
Interventional
2. Study Status
Record Verification Date
October 2017
Overall Recruitment Status
Unknown status
Study Start Date
August 28, 2017 (Actual)
Primary Completion Date
August 2018 (Anticipated)
Study Completion Date
November 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NHS Greater Glasgow and Clyde
Collaborators
Rocket Medical plc
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Malignant Pleural Effusion (MPE) is a collection of fluid inside the chest caused by cancer. It is a common medical problem and often causes severe breathlessness. Patients with this condition generally have a very poor survival and so it is extremely important that they are given effective treatment as soon as possible to minimise the amount of time they have to spend in hospital.
Standard treatment for MPE involves an admission to hospital to drain the fluid and then attempt to prevent the fluid from returning by sticking the lung to the inside of the rib cage with medical talc powder which acts like glue. This is called talc pleurodesis (TP) but unfortunately it fails in about 30% of patients. This is usually because the lung has not fully re-expanded and has not made contact with the inside of the ribs. When this happens, the fluid can be effectively treated with a different type of drainage tube called an indwelling pleural catheter (IPC) which tunnels under the skin and is drained at home by the district nurses.
It is thought that pressure measurements taken from the fluid as it is drained may be able to show doctors whether or not the lung will re-expand before patients are committed to either TP or an IPC. In this research we wish to test if these measurements can be used to choose which is the best first treatment option (TP or IPC) for patients with MPE. We have called this 'EDIT management'. Since it is uncertain whether this new approach will work, patients will be randomised to have either standard treatment or EDIT management. We will compare the two groups to assess whether the patients who had EDIT management had to have fewer repeat procedures over the following 3 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pleural Effusion, Malignant
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
EDIT Management
Arm Type
Experimental
Arm Title
Standard Care
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
EDIT Management
Intervention Description
EDIT management
Volumetric Pleural MRI for pre-aspiration pleural cavity volume
Large volume pleural aspiration with recording of intra-pleural pressure during aspiration
Volumetric Pleural MRI for post-aspiration pleural cavity volume
Computation of PEL250, defined as the rolling average of pleural elastance over the preceding 250ml aspirated.
MaxPEL250 ≥ 14.5 cm H2O/L: allocated to 1st-line IPC MaxPEL250 < 14.5 cm H2O/L: allocated to 1st-line TP
EDIT-directed 1st-line treatment to be delivered within 24 hours; if insufficient residual pleural fluid to allow standard Seldinger insertion technique then Boutin-type needle used for pneumothorax induction and guide wire insertion.
Intervention Type
Procedure
Intervention Name(s)
Chest drain and talc pleurodesis
Intervention Description
Intercostal chest drain insertion and talc slurry instillation according to British Thoracic Society guidelines
Primary Outcome Measure Information:
Title
Feasibility of recruiting 30 patients within 12 months and randomising them to either EDIT Management or Standard Care
Description
The number of patients recruited and randomised within 12 months
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Failure rate of the manometry procedure
Description
Defined as the proportion of patients in whom PEL cannot be computed
Time Frame
12 months
Title
Incidence of adverse events associated with the manometry procedure
Description
Number of participants with Adverse Events (AEs) and Serious AEs (SAEs), defined by United Kingdom Good Clinical Practice in Research, associated with use of the digital pleural manometer
Time Frame
12 months
Title
Aspiration threshold to detect abnormal pleural elastance
Description
The pleural fluid aspiration volume at which the rolling average pleural elastance over the preceding 250ml (PEL250) first exceeds the upper limit of normal (14.5cm H2O/L).
Time Frame
12 months
Title
Proportion of patients requiring pneumothorax induction following manometry
Description
The proportion of patients in which pneumothorax induction is required to facilitate safe intercostal chest drain/IPC insertion in the EDIT arm (Group A)
Time Frame
12 months
Title
Assess accuracy of pleural cavity volume change assumptions
Description
To test the assumption that pleural cavity volume change is equivalent to the volume of pleural fluid removed during aspiration by measuring:
Pleural fluid aspiration volume
Pleural cavity volume change, as measured directly using volumetric Magnetic Resonance Imaging (MRI), calculated as pre- minus post-aspiration pleural cavity volume
Time Frame
12 months
Title
Assess accuracy of ultrasound effusion volume estimate
Description
To test the accuracy of a predictive model of pleural effusion volume based on thoracic ultrasound measurements by measuring:
Thoracic ultrasound estimated total pleural effusion volume
Pre-pleural fluid aspiration pleural cavity volume measured by volumetric MRI
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinically confident diagnosis of malignant pleural effusion, defined as any of the following:
Pleural effusion with histocytologically proven pleural malignancy OR
Pleural effusion in the context of histocytologically proven malignancy elsewhere, without a clear alternative cause for fluid OR
Pleural effusion with typical features of malignancy with pleural involvement on cross-sectional imaging (CT/MRI)
Degree of breathlessness for which therapeutic pleural intervention would be offered
Age >18 years
Expected survival > 3 months
Written Informed Consent
Exclusion Criteria:
Females who are pregnant or lactating
Clinical suspicion of non-expansile lung for which talc pleurodesis would not be offered
Patient preference for 1st-line indwelling pleural catheter (IPC) insertion
Previous ipsilateral failed talc pleurodesis
Estimated pleural fluid volume ≤ 1 litre, as defined by thoracic ultrasound
Any contraindication to chest drain or IPC insertion, including:
Irreversible coagulopathy Inaccessible pleural collection, including lack of suitable IPC tunnel site
- Any contraindication to MRI scanning, including:
Claustrophobia Cardiac pacemaker Ferrous metal implants or retained ferrous metal foreign body Previously documented reaction to Gadolinium-containing intravenous contrast agent Significant renal impairment (eGFR<30 ml/min)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Joanne McGarry
Phone
+ 44 141 232 1818
Email
joanne.mcgarry@ggc.scot.nhs.uk
Facility Information:
Facility Name
Queen Elizabeth University Hospital
City
Glasgow
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kevin Blyth, MD
Email
kevin.blyth@ggc.scot.nhs.uk
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
31374208
Citation
Martin GA, Tsim S, Kidd AC, Foster JE, McLoone P, Chalmers A, Blyth KG. Pre-EDIT: A Randomized Feasibility Trial of Elastance-Directed Intrapleural Catheter or Talc Pleurodesis in Malignant Pleural Effusion. Chest. 2019 Dec;156(6):1204-1213. doi: 10.1016/j.chest.2019.07.010. Epub 2019 Jul 30.
Results Reference
derived
PubMed Identifier
29862030
Citation
Martin GA, Tsim S, Kidd AC, Foster JE, McLoone P, Chalmers A, Blyth KG. Pre-EDIT: protocol for a randomised feasibility trial of elastance-directed intrapleural catheter or talc pleurodesis (EDIT) in malignant pleural effusion. BMJ Open Respir Res. 2018 May 29;5(1):e000293. doi: 10.1136/bmjresp-2018-000293. eCollection 2018.
Results Reference
derived
Learn more about this trial
EDIT Management Feasibility Trial
We'll reach out to this number within 24 hrs